<DOC>
	<DOCNO>NCT00437268</DOCNO>
	<brief_summary>To see well enzastaurin combination irinotecan cetuximab work versus irinotecan cetuximab patient progress within 3 month .</brief_summary>
	<brief_title>A Study Irinotecan Plus Cetuximab With Without Enzastaurin Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients eligible include study meet follow criterion : 1 . Histologic diagnosis colorectal cancer . 2 . Performance status 0 , 1 , 2 ECOG performance status schedule . 3 . Have document disease progression accord Response Evaluation Criteria Solid Tumors ( RECIST ; Therasse et al . 2000 ) within 3 month receive FOLFOX plus bevacizumab firstline therapy locally advance metastatic disease , within 6 month receive FOLFOX without bevacizumab adjuvant set . 4 . Standard radiation therapy rectal cancer allow . Patients must recover toxic effect ( except alopecia ) treatment prior study enrollment . Prior radiotherapy must complete 4 week study entry . Lesions radiate advanced setting include site measurable disease unless clear tumor progression document lesion since end radiation therapy . 5 . At least one unidimensionally measurable lesion meeting RECIST guideline ( least 10 mm long diameter spiral computerize tomography [ CT ] scan , least 20 mm standard technique ) . Positron emission tomography [ PET ] scan ultrasound may use . Patients exclude study meet follow criterion : 1 . Have receive treatment within last 4 week drug receive regulatory approval indication time study entry . 2 . Have previously complete withdrawn study study investigate enzastaurin , irinotecan , cetuximab . 3 . Have serious concomitant systemic disorder ( eg , active infection include HIV , cardiac disease ) , opinion investigator , would compromise patient 's ability adhere protocol . 4 . Have serious cardiac condition , myocardial infarction within 6 month , angina , heart disease , define New York Heart Association Class III IV . 5 . Have prior malignancy ( colorectal cancer , adequately treat carcinoma situ cervix nonmelanoma skin cancer ) , unless prior malignancy diagnose definitively treat least 5 year previously subsequent evidence recurrence . Patients history low grade ( Gleason score less equal 6 ) localize prostate cancer eligible even diagnose less 5 year previously .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>